Preparation, Controlled Drug Release, and Cell Viability Evaluation of Tenofovir Alafenamide-Loaded Chitosan Nanoparticles

Basit Öğe Kaydı
dc.authoridUlu, Ahmet/0000-0002-4447-6233
dc.authoridKorkmaz Sezer, Selcen/0000-0001-9479-3176
dc.authoridAteş, Burhan/0000-0001-6080-229X
dc.authorwosidUlu, Ahmet/L-5180-2016
dc.authorwosidKorkmaz Sezer, Selcen/ABU-1678-2022
dc.authorwosidAteş, Burhan/AAA-3730-2021
dc.contributor.authorUlu, Ahmet
dc.contributor.authorSezer, Selcen Korkmaz
dc.contributor.authorYuksel, Sengul
dc.contributor.authorKoc, Ahmet
dc.contributor.authorAtes, Burhan
dc.date.accessioned2024-08-04T20:50:52Z
dc.date.available2024-08-04T20:50:52Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractTenofovir alafenamide (TAF) is used as a hepatitis B virus (HBV) nucleotide reverse transcriptase inhibitor for the treatment of chronic HBV infection. However, the use of TAF suffers from its poor solubility and low bioavailability. Therefore, this study prepared and characterized chitosan nanoparticles (CHS NPs) loaded with TAF. Morphological findings demonstrated that CHS NPs are roughly spherical and homogeneous in shape. Besides, TAF-loaded CHS NPs displayed the hydrodynamic diameter, zeta potential, and PDI of approximately 340 nm, 48.9 mV, and 0.65, respectively. The encapsulation efficiency is at about 50%, and TAF is released about 93% at the end of 80 hours at pH 7.4. In addition, human hepatocellular carcinoma cells (HepG2) are used for cell viability studies and it is observed that TAF-loaded CHS NPs has 1.24 times less viable cells as compared to the control. Collectively, TAF-loaded CHS NPs could be used as an efficient formulation for the treatment of chronic HBV infection.en_US
dc.description.sponsorshipInonu University Scientific Research Projects Unit [TCD-2018-1356]en_US
dc.description.sponsorshipThe authors are very grateful to nonu University. Financial support for this research was provided by nonu University Scientific Research Projects Unit (TCD-2018-1356).en_US
dc.identifier.doi10.1002/star.202100144
dc.identifier.issn0038-9056
dc.identifier.issn1521-379X
dc.identifier.issue1-2en_US
dc.identifier.scopus2-s2.0-85119504228en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1002/star.202100144
dc.identifier.urihttps://hdl.handle.net/11616/100319
dc.identifier.volume76en_US
dc.identifier.wosWOS:000720736400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWiley-V C H Verlag Gmbhen_US
dc.relation.ispartofStarch-Starkeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchitosan nanoparticlesen_US
dc.subjectdrug releaseen_US
dc.subjectHBV preventionen_US
dc.subjecttenofovir alafenamideen_US
dc.titlePreparation, Controlled Drug Release, and Cell Viability Evaluation of Tenofovir Alafenamide-Loaded Chitosan Nanoparticlesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu